Winners announced for 2025 PM Society Awards
March 31, 2025Industry Associations, Research and Development Pharmacy, awards, pharma industry, pm society
The pharma marketing and healthcare communications industry gathered for the 39th PM Society Awards on 14 March 2025, which celebrates …
FDA grants fast track designation to chlamydia vaccine candidate
March 28, 2025Research and Development FDA, Infections and infestations, Sanofi, chlamydia, vaccination
The US Food and Drug Association (FDA) has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention …
Shane Olwill appointed as chief development officer at Asgard Therapeutics
March 28, 2025Business Services, Clinical Research Asgard Therapeutics, CDO, Oncology, appointment, immunology
Asgard Therapeutics has announced the appointment of Shane Olwill as chief development officer (CDO). The biotech company develops in vivo …
Gergely Sved appointed as CEO of Ellab
March 28, 2025Contract Sales Organisations, Sales and Marketing CEO, Ellab, Pharmacy, appointment, life sciences
Ellab has announced that it has appointed Gergely Sved as its new chief executive officer (CEO). The company provides validation, …
Carole Imbert appointed as CFO of Vect-Horus
March 28, 2025Biotech/start-up, Sales and Marketing Pharmacy, Vect-Horus, appointment, biotech, cfo
Vect-Horus has announced it has appointed Carole Imbert as chief financial officer (CFO) and to its executive committee. Vect-Horus is …
Five of EU-27 account for 68% of pharma trade, report finds
March 27, 2025Market Research Logista Freight, Pharmacy, european union, market report, trade
Logista Freight has found that Germany, France, Belgium, Italy and the Netherlands account for up to 68% of trade in …
Pierre Fabre announces investments and partnerships in lung cancer research
March 27, 2025Research and Development Oncology, Pierre Fabre Laboratories, lung cancer treatment, oncology
Pierre Fabre Laboratories has announced investment and partnership plans to improve the lives of lung cancer patients with unmet needs. …
Allegro shares promising preclinical results for osteoarthritis treatment
March 26, 2025Clinical Trial Services, Research and Development Allegro, Orthopaedics, biomedical, clinical studies, osteoarthritis
Allegro has announced that hydrocelin, its injectable microparticle hydrogel, showed no signs of toxicity in two preclinical studies. Allegro is …
Pharming Group doses first patient in phase 2 trial of leniolisib in CVID
March 26, 2025Clinical Trial Services, Research and Development CVID, Immunology, Pharming Group, clinical trial, common variable immunodeficiency, immunodeficiency
Pharming Group has announced that the first patient has been dosed in a phase 2 clinical trial evaluating leniolisib in …
Cold Chain Technologies acquires Global Cold Chain Solutions
March 26, 2025Dedicated cold-chain delivery, Manufacturing and Production Global Cold Chain Solutions, Pharmacy, business development, cold chain, life sciences, partnership
Cold Chain Technologies (CCT), a global provider for temperature-sensitive packing and digital solutions, has acquired Global Cold Chain Solutions (GCCS), …
Gary Lyons appointed as EVP medical affairs of Coronado Research
March 26, 2025Business Services, Consultancy Consultancy, Coronado Research, Medical Affairs, Pharmacy, appointment
Coronado Research, a UK-based consultancy-led organisation, has announced that it has appointed Gary Lyons as executive vice president (EVP) for …
Takeda announces launch of Framework to help support patient access to life-extending combination treatments
February 25, 2025Business Services Cancer, HIV/AIDS, Immunology, NHS, NICE, Oncology, Takeda, VPAG, patient access
The Conceptual Implementation Framework outlines critical points within the UK healthcare access ecosystem to help improve the introduction of combination …
Recce Pharmaceuticals reports positive phase 2 data for skin infection drug
February 17, 2025Research and Development Recce, Skin, diabetes, skin, skin infections
Recce Pharmaceuticals have announced positive patient data from its phase 2 clinical trial into RECCE 327 (R327), for the treatment …
PulseSight Therapeutics closes Series A financing for dry AMD phase 1 clinical study
February 14, 2025Clinical Research Opthalmology, age-related macular degeneration, clinical trials
Ophthalmology biotech PulseSight Therapeutics has confirmed the closure of its Series A funding round, the proceeds of which will be …
Cardinal Health’s Kangaroo OMNI™ Enteral Feeding Pump to launch in new international markets in 2025
February 6, 2025Sales and Marketing Kangaroo, enteral, feeding pump
The next generation Kangaroo OMNI™ enteral feeding pump delivers nutrition and hydration from hospital to home. DUBLIN, Ireland, Feb.4, 2025 …
European Commission launches new Biotech and Biomanufacturing Hub
February 3, 2025Research and Development Biomanufacturing, Corporate, European Commission, Hub, european union
The European Commission has announced the opening of a new Biotech and Biomanufacturing Hub, supporting start-ups and small- to medium-sized …
FlyPharma 2025 Amsterdam officially announced as contracts are signed with host sponsors
February 3, 2025Business Services, Conferences Air France KLM Martinair Cargo ., Amsterdam Airport Schiphol, Corporate, DHL Global Forwarding, FlyPharma Conferences, logistics
FlyPharma, the leading platform for the pharmaceutical logistics and supply chain industry, is thrilled to announce its ninth European conference, …
Prenatal care could be revolutionised suggests studies from BrightHeart
January 31, 2025Research and Development AI, BrightHeart, FDA, Obstetrics & Gynaecology, prenatal, studies
Private medical device and artificial intelligence (AI)-led company, BrightHeart, has revealed two studies which show an improvement to pre-natal care …
CANDOR Bioscience acquired by Medix Biochemica
January 31, 2025Sales and Marketing CANDOR biosciences, Diagnostics, Medix biochemica, acquisition, in vitro diagnostics
CANDOR Biosciences, a supplier in immunoassay solutions, has been acquired by Medix Biochemica, a supplier of raw materials for in …
MHRA approve new treatment combo for transplant-ineligible multiple myeloma patients
January 30, 2025Research and Development MHRA, Oncology, approvals, multiple myeloma, rare diseases
The Medicine and Healthcare products Regulatory Agency (MHRA) has approved quadruplet therapy, SARCLISA (isatuximab) in combination to treat multiple myeloma …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
